Published in PLoS One on June 10, 2013
The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer (2015) 2.74
Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal (2014) 1.61
TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell (2017) 1.41
B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One (2013) 1.38
MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget (2015) 1.07
Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. EMBO J (2014) 1.04
The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med (2014) 0.99
Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res (2014) 0.99
Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio (2015) 0.92
Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol (2014) 0.90
Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression. Oncogene (2014) 0.90
Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. Clin Cancer Res (2015) 0.90
Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-β. Oncotarget (2015) 0.90
Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ Cell Rep (2015) 0.90
YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget (2015) 0.89
Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene (2015) 0.86
Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS One (2014) 0.85
E2A suppresses invasion and migration by targeting YAP in colorectal cancer cells. J Transl Med (2013) 0.84
Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model. Mol Cell Biol (2014) 0.84
FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. Oncotarget (2015) 0.83
TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells. Mol Med Rep (2014) 0.83
The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol (2016) 0.82
Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One (2013) 0.82
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells. Oncotarget (2016) 0.81
Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction. Diagn Pathol (2014) 0.81
Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol (2014) 0.81
Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target. Oncogene (2014) 0.81
TAZ and YAP are frequently activated oncoproteins in sarcomas. Oncotarget (2016) 0.80
Lysophosphatidic acid induces YAP-promoted proliferation of human corneal endothelial cells via PI3K and ROCK pathways. Mol Ther Methods Clin Dev (2015) 0.80
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. Pharmacogenomics J (2015) 0.80
CDK1 phosphorylation of TAZ in mitosis inhibits its oncogenic activity. Oncotarget (2015) 0.80
Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer. Oncotarget (2017) 0.80
Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol (2015) 0.79
Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. World J Gastroenterol (2016) 0.79
The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. J Pathol (2016) 0.79
Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer. Oncol Lett (2015) 0.78
Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis. PLoS One (2015) 0.78
Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int J Clin Exp Pathol (2015) 0.78
TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells. J Biol Chem (2015) 0.78
The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway. Oncotarget (2016) 0.77
High expression of TAZ indicates a poor prognosis in retinoblastoma. Diagn Pathol (2015) 0.77
Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP. J Virol (2016) 0.76
Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer. J Hematol Oncol (2017) 0.75
Expression of Yes-associated protein (YAP) in breast phyllodes tumor. Int J Clin Exp Pathol (2014) 0.75
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J (2016) 0.75
Prognostic significance of a component of the Hippo pathway, TAZ, in human uterine endometrioid adenocarcinoma. Oncol Lett (2016) 0.75
The clinical significance of forkhead box protein A1 and its role in colorectal cancer. Mol Med Rep (2016) 0.75
TAZ promotes cell growth and inhibits Celastrol-induced cell apoptosis. Biosci Rep (2016) 0.75
Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway. Oncotarget (2016) 0.75
TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma. Oncotarget (2017) 0.75
Prognostic significance of TAZ expression in various cancers: a meta-analysis. Onco Targets Ther (2016) 0.75
Regulation of TAZ in cancer. Protein Cell (2016) 0.75
The role of transcriptional coactivator TAZ in gliomas. Oncotarget (2016) 0.75
G-protein-coupled receptors mediate ω-3 PUFAs-inhibited colorectal cancer by activating the Hippo pathway. Oncotarget (2016) 0.75
USP21 regulates Hippo pathway activity by mediating MARK protein turnover. Oncotarget (2017) 0.75
Upregulation of Yes-associated protein and transcriptional co-activator with PDZ-binding motif influences the behavior of LOVO human colon adenocarcinoma cells. Exp Ther Med (2017) 0.75
Transcriptional co-activator with PDZ-binding motif overexpression promotes cell proliferation and transcriptional co-activator with PDZ-binding motif deficiency induces cell cycle arrest in neuroblastoma. Oncol Lett (2017) 0.75
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 8.11
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell (2003) 7.43
Hippo signaling in organ size control. Genes Dev (2007) 6.29
The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell (2008) 5.58
Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem (2007) 5.49
TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev (2001) 5.41
The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell (2009) 5.19
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell (2005) 5.10
From cell structure to transcription: Hippo forges a new path. Cell (2006) 4.65
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J (2000) 4.55
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res (2008) 4.33
The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol (2008) 3.63
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila. Curr Biol (2008) 3.39
TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem (2009) 3.20
Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol (2006) 3.15
Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A (2007) 2.31
Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol (2008) 2.24
The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol (2012) 2.21
The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J (2005) 2.15
Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg (2008) 2.02
TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem (2009) 1.96
TAZ is a novel oncogene in non-small cell lung cancer. Oncogene (2011) 1.85
TAZ expression as a prognostic indicator in colorectal cancer. PLoS One (2013) 1.55
YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle (2012) 1.34
WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene (2010) 1.29
Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer (2011) 1.24
Wbp2 cooperates with Yorkie to drive tissue growth downstream of the Salvador-Warts-Hippo pathway. Cell Death Differ (2011) 1.06
Modeling human cancer: report on the Eighth Beatson International Cancer Conference. Cancer Res (2005) 0.93
Sub-diffraction-limited optical imaging with a silver superlens. Science (2005) 7.67
Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity (2008) 5.82
Plasmon lasers at deep subwavelength scale. Nature (2009) 4.93
Three-dimensional optical metamaterial with a negative refractive index. Nature (2008) 4.87
A graphene-based broadband optical modulator. Nature (2011) 4.21
A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med (2009) 4.20
An optical cloak made of dielectrics. Nat Mater (2009) 4.16
Far-field optical hyperlens magnifying sub-diffraction-limited objects. Science (2007) 4.14
Optical negative refraction in bulk metamaterials of nanowires. Science (2008) 3.28
Ultrasonic metamaterials with negative modulus. Nat Mater (2006) 2.91
Plasmon-induced transparency in metamaterials. Phys Rev Lett (2008) 2.88
Experimental demonstration of an acoustic magnifying hyperlens. Nat Mater (2009) 2.82
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Photonic spin Hall effect at metasurfaces. Science (2013) 2.04
MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One (2010) 1.94
Phase mismatch-free nonlinear propagation in optical zero-index materials. Science (2013) 1.90
Edge nonlinear optics on a MoS₂ atomic monolayer. Science (2014) 1.83
Room-temperature sub-diffraction-limited plasmon laser by total internal reflection. Nat Mater (2010) 1.73
Switching terahertz waves with gate-controlled active graphene metamaterials. Nat Mater (2012) 1.72
Probing the electromagnetic field of a 15-nanometre hotspot by single molecule imaging. Nature (2011) 1.72
Space-time crystals of trapped ions. Phys Rev Lett (2012) 1.71
Photoinduced handedness switching in terahertz chiral metamolecules. Nat Commun (2012) 1.69
Flying plasmonic lens in the near field for high-speed nanolithography. Nat Nanotechnol (2008) 1.65
Spherical hyperlens for two-dimensional sub-diffractional imaging at visible frequencies. Nat Commun (2010) 1.61
Transformational plasmon optics. Nano Lett (2010) 1.61
Plasmonic Luneburg and Eaton lenses. Nat Nanotechnol (2011) 1.59
DISCO: distance and spectrum correlation optimization alignment for two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Anal Chem (2010) 1.58
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood (2009) 1.58
Sex hormone ratio changes in men and postmenopausal women with coronary artery disease. Menopause (2007) 1.56
Double-layer graphene optical modulator. Nano Lett (2012) 1.56
A carpet cloak for visible light. Nano Lett (2011) 1.55
Negative refractive index in chiral metamaterials. Phys Rev Lett (2009) 1.55
High-Q surface-plasmon-polariton whispering-gallery microcavity. Nature (2009) 1.52
All optical interface for parallel, remote, and spatiotemporal control of neuronal activity. Nano Lett (2007) 1.49
Wavelet- and Fourier-transform-based spectrum similarity approaches to compound identification in gas chromatography/mass spectrometry. Anal Chem (2011) 1.49
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell (2007) 1.45
Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry peak sorting algorithm. J Chromatogr A (2007) 1.42
Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol (2003) 1.41
MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. Biochem Biophys Res Commun (2012) 1.40
Far-field optical superlens. Nano Lett (2007) 1.39
Common aspects of human and primate seronegative arthritis. J Rheumatol (2004) 1.39
Focusing surface plasmons with a plasmonic lens. Nano Lett (2005) 1.39
Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol (2012) 1.37
Performance evaluation of existing de novo sequencing algorithms. J Proteome Res (2006) 1.36
Metamaterials: a new frontier of science and technology. Chem Soc Rev (2011) 1.34
Compound identification using partial and semipartial correlations for gas chromatography-mass spectrometry data. Anal Chem (2012) 1.34
Light-driven nanoscale plasmonic motors. Nat Nanotechnol (2010) 1.33
Observation of stimulated emission of surface plasmon polaritons. Nano Lett (2008) 1.32
Maskless plasmonic lithography at 22 nm resolution. Sci Rep (2011) 1.31
Cloaking of matter waves. Phys Rev Lett (2008) 1.28
A method of calculating the second dimension retention index in comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry. J Chromatogr A (2011) 1.28
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A (2010) 1.28
A method of finding optimal weight factors for compound identification in gas chromatography-mass spectrometry. Bioinformatics (2012) 1.27
Axon initiation and growth cone turning on bound protein gradients. J Neurosci (2009) 1.27
Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun (2007) 1.27
The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J Biol Chem (2006) 1.27
Strong coupling of surface plasmon polaritons in monolayer graphene sheet arrays. Phys Rev Lett (2012) 1.27
Identification and association of the single nucleotide polymorphisms in calpain3 (CAPN3) gene with carcass traits in chickens. BMC Genet (2009) 1.26
Self-amplifying autocrine actions of BDNF in axon development. Proc Natl Acad Sci U S A (2011) 1.25
NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol Biochem (2008) 1.24
MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett (2012) 1.22
An optimal peak alignment for comprehensive two-dimensional gas chromatography mass spectrometry using mixture similarity measure. Bioinformatics (2011) 1.22
N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res (2008) 1.22
Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res (2005) 1.21
Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China. Trop Med Int Health (2007) 1.21
Roles of GRP78 in physiology and cancer. J Cell Biochem (2010) 1.20
Subwavelength discrete solitons in nonlinear metamaterials. Phys Rev Lett (2007) 1.20
MetSign: a computational platform for high-resolution mass spectrometry-based metabolomics. Anal Chem (2011) 1.19
Measuring financial protection for health in families with chronic conditions in Rural China. BMC Public Health (2012) 1.18
Neural network prediction of peptide separation in strong anion exchange chromatography. Bioinformatics (2006) 1.17
TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (2012) 1.15
Passivation mechanism of thermal atomic layer-deposited Al2O3 films on silicon at different annealing temperatures. Nanoscale Res Lett (2013) 1.15
The effect of nonsense codons on splicing: a genomic analysis. RNA (2003) 1.15
Infection and propagation of human rhinovirus C in human airway epithelial cells. J Virol (2012) 1.14
Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS (2004) 1.13
Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis (2009) 1.13
Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology (2006) 1.13
Development of optical hyperlens for imaging below the diffraction limit. Opt Express (2007) 1.13
Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology (2004) 1.13
Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells. Kidney Int (2010) 1.12
Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer (2005) 1.12
Intein-mediated biotinylation of proteins and its application in a protein microarray. J Am Chem Soc (2002) 1.12
Nonparaxial Mathieu and Weber accelerating beams. Phys Rev Lett (2012) 1.11
Hantaan virus RNA load in patients having hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis (2012) 1.11
iMatch: a retention index tool for analysis of gas chromatography-mass spectrometry data. J Chromatogr A (2011) 1.11
A hierarchical statistical model to assess the confidence of peptides and proteins inferred from tandem mass spectrometry. Bioinformatics (2007) 1.11
How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev (2009) 1.10
Environmental epigenetics and its implication on disease risk and health outcomes. ILAR J (2012) 1.10
Health-related quality of life in patients with high-grade glioma. Neuro Oncol (2008) 1.10
Heterojunction silicon microwire solar cells. Nano Lett (2012) 1.10
Mechanism of flexural resonance frequency shift of a piezoelectric microcantilever sensor during humidity detection. Appl Phys Lett (2008) 1.09
New enlightenment of French Paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther (2007) 1.09
Expression of androgen receptor is negatively regulated by p53. Neoplasia (2007) 1.08
Multiplexed and electrically modulated plasmon laser circuit. Nano Lett (2012) 1.08
Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. OMICS (2004) 1.08